Please note: The information displayed on this page might be outdated.
CytomX Therapeutics, Inc.: Antibody prodrug (Probody) platform. Probody therapeutics with protease-cleavable masks are designed to selectively bind within the tumor microenvironment. CytomX is currently developing partnered and wholly-owned checkpoint inhibitors, Probody drug conjugates (PDC), T-cell bispecifics and CARs. Lead program CX-072 is a wholly owned PD-L1 Probody currently being studied in a Phase 1/2 study as monotherapy and in combination with ipilimumab and with vemurafenib. CX-2009 is a CD166-targeted PDC currently being studied in a Phase 1/2 study in solid tumors. BMS-partnered Probody of ipilimumab being studied in ongoing Phase 1/2 trial in monotherapy and in combination with nivolumab. AbbVie partnered CD71-targeted PDC to enter clinic 2018. Amgen collaboration on T-cell engaging bispecific Probody therapeutics.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase l or ll
Disease Space
Immunotherapy, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies
Website:
Address:
151 Oyster Point Blvd
Suite 400
South San Francisco, CA 94080
United States

Company Participants at 2018 Trout CEO & Investor Ski Conference

  • Sean McCarthy, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.